Your browser doesn't support javascript.
Evaluation of Low-Dose Aspirin use among Critically Ill Patients with COVID-19: A Multicenter Propensity Score Matched Study.
Al Harthi, Abdullah F; Aljuhani, Ohoud; Korayem, Ghazwa B; Altebainawi, Ali F; Alenezi, Raghdah S; Al Harbi, Shmeylan; Gramish, Jawaher; Kensara, Raed; Hafidh, Awattif; Al Enazi, Huda; Alawad, Ahad; Alotaibi, Rand; Alshehri, Abdulaziz; Alhuthaili, Omar; Vishwakarma, Ramesh; Bin Saleh, Khalid; Alsulaiman, Thamer; Alqahtani, Rahaf Ali; Hussain, Sajid; Almazrou, Saja; Al Sulaiman, Khalid.
  • Al Harthi AF; Pharmaceutical Care Department, 48168King Abdulaziz Medical City, Riyadh, Saudi Arabia.
  • Aljuhani O; College of Pharmacy, 48149King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia.
  • Korayem GB; 309817King Abdullah International Medical Research Center, Riyadh, Saudi Arabia.
  • Altebainawi AF; Department of Pharmacy Practice, Faculty of Pharmacy, 37848King Abdulaziz University, Jeddah, Saudi Arabia.
  • Alenezi RS; Saudi Critical Care Pharmacy Research (SCAPE) Platform, Saudi Arabia.
  • Al Harbi S; Department of Pharmacy Practice, College of Pharmacy, 112893Princess Nourah Bint Abdulrahman University, Riyadh, Saudi Arabia.
  • Gramish J; Pharmaceutical Care Services, King Salman Specialist Hospital, Hail Health Cluster, Ministry of Health, Hail, Saudi Arabia.
  • Kensara R; College of Pharmacy, 48138University of Hail, Hail Saudi Arabia.
  • Hafidh A; Pharmaceutical Care Department, 48168King Abdulaziz Medical City, Riyadh, Saudi Arabia.
  • Al Enazi H; College of Pharmacy, 48149King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia.
  • Alawad A; 309817King Abdullah International Medical Research Center, Riyadh, Saudi Arabia.
  • Alotaibi R; Pharmaceutical Care Department, 48168King Abdulaziz Medical City, Riyadh, Saudi Arabia.
  • Alshehri A; College of Pharmacy, 48149King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia.
  • Alhuthaili O; 309817King Abdullah International Medical Research Center, Riyadh, Saudi Arabia.
  • Vishwakarma R; Pharmaceutical Care Department, 48168King Abdulaziz Medical City, Riyadh, Saudi Arabia.
  • Bin Saleh K; 309817King Abdullah International Medical Research Center, Riyadh, Saudi Arabia.
  • Alsulaiman T; Department of Pharmacy Practice, Faculty of Pharmacy, 37848King Abdulaziz University, Jeddah, Saudi Arabia.
  • Alqahtani RA; Pharmaceutical Care Department, 48168King Abdulaziz Medical City, Riyadh, Saudi Arabia.
  • Hussain S; 309817King Abdullah International Medical Research Center, Riyadh, Saudi Arabia.
  • Almazrou S; Department of Pharmacy Practice, College of Pharmacy, 112893Princess Nourah Bint Abdulrahman University, Riyadh, Saudi Arabia.
  • Al Sulaiman K; Department of Pharmacy Practice, College of Pharmacy, 112893Princess Nourah Bint Abdulrahman University, Riyadh, Saudi Arabia.
J Intensive Care Med ; 37(9): 1238-1249, 2022 Sep.
Article in English | MEDLINE | ID: covidwho-1808050
ABSTRACT

BACKGROUND:

Aspirin is widely used as a cardioprotective agent due to its antiplatelet and anti-inflammatory properties. The literature has assessed and evaluated its role in hospitalized COVID-19 patients. However, no data are available regarding its role in COVID-19 critically ill patients. This study aimed to evaluate the use of low-dose aspirin (81-100 mg) and its impact on outcomes in critically ill patients with COVID-19.

METHOD:

A multicenter, retrospective cohort study of all critically ill adult patients with confirmed COVID-19 admitted to intensive care units (ICUs) between March 1, 2020, and March 31, 2021. Eligible patients were classified into two groups based on aspirin use during ICU stay. The primary outcome was in-hospital mortality, and other outcomes were considered secondary. Propensity score matching was used (11 ratio) based on the selected criteria.

RESULTS:

A total of 1033 patients were eligible, and 352 patients were included after propensity score matching. The in-hospital mortality (HR 0.73 [0.56, 0.97], p = 0.03) was lower in patients who received aspirin during stay. Conversely, patients who received aspirin had a higher odds of major bleeding than those in the control group (OR 2.92 [0.91, 9.36], p = 0.07); however, this was not statistically significant. Additionally, subgroup analysis showed a possible mortality benefit for patients who used aspirin therapy prior to hospitalization and continued during ICU stay (HR 0.72 [0.52, 1.01], p = 0.05), but not with the new initiation of aspirin (HR 1.22 [0.68, 2.20], p = 0.50).

CONCLUSION:

Continuation of aspirin therapy during ICU stay in critically ill patients with COVID-19 who were receiving it prior to ICU admission may have a mortality benefit; nevertheless, it may be associated with an increased risk of significant bleeding. Appropriate evaluation for safety versus benefits of utilizing aspirin therapy during ICU stay in COVID19 critically ill patients is highly recommended.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Limits: Adult / Humans Language: English Journal: J Intensive Care Med Journal subject: Critical Care Year: 2022 Document Type: Article Affiliation country: 08850666221093229

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Limits: Adult / Humans Language: English Journal: J Intensive Care Med Journal subject: Critical Care Year: 2022 Document Type: Article Affiliation country: 08850666221093229